BioPharmSignal logoBioPharmSignal

Biotech News

ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1

GSK plc (GSK)GSK plcCompany update

Results illustrate ViiV Healthcare’s pipeline is generating multiple options for the development of new ultra long-acting HIV regimens.

Related news

GSKGSK plc2026-10-06 14:00 EST

ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia

GSKGSK plc2026-10-16 13:49 EST

GSK showcases pipeline momentum across lung, gynaecological and gastrointestinal cancers at ESMO 2026

LEGNLegend Biotech Corporation2026-11-04 14:00 EST

Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026

BMYBMYBristol-Myers Squibb Company2026-10-19 10:59 EST

Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026

COGTCogent Biosciences2026-10-27 20:01 EST

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

LEGNLegend Biotech Corporation2026-10-01 13:00 EST

Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

SNYSanofi2026-10-01 05:00 EST

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

REGNRegeneron Pharmaceuticals2026-10-01 05:00 EST

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

BCRXBioCryst Pharmaceuticals2026-10-05 11:00 EST

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

View all latest news

GSK plc

Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...

Recent company news

GSKGSK plc2026-11-05 15:08 EST

GSK showcases progress in liver portfolio at AASLD 2026

GSKGSK plc2026-10-28 07:00 EST

GSK delivers strong Q3 performance and continued momentum

GSKGSK plc2026-10-26 15:30 EST

Ris-Rez reduced risk of disease progression or death by 67% versus chemotherapy in patients with relapsed osteosarcoma in China

GSKGSK plc2026-10-24 23:00 EST

Jemperli (dostarlimab) data show 76% of patients with MSI-H/dMMR locally advanced rectal cancer achieved a complete response

GSKGSK plc2026-10-23 23:00 EST

GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer

Stock data

Close
50.41 USD
Market cap
98.26B USD
Exchange
NYSE
Sector
Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
Location
United States